JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB306215

APC Anti-CD16 antibody [SP189] (C-terminal)

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal CD16a antibody - conjugated to APC.

View Alternative Names

CD16a, CD16A, FCG3, FCGR3, IGFR3, FCGR3A, Low affinity immunoglobulin gamma Fc region receptor III-A, IgG Fc receptor III-A, CD16-II, CD16a antigen, Fc-gamma RIII-alpha, FcR-10, IgG Fc receptor III-2, Fc-gamma RIII, Fc-gamma RIIIa, FcRIII, FcRIIIa, FcgammaRIIIA

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-CD16 antibody [SP189] - C-terminal

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-CD16 antibody [SP189] - C-terminal

  • 603 Alexa Fluor® 568

    Alexa Fluor® 568 Anti-CD16 antibody [SP189] - C-terminal

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-CD16 antibody [SP189] - C-terminal

  • Unconjugated

    Anti-CD16a antibody [SP189] - C-terminal

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-CD16 antibody [SP189] - C-terminal

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-CD16a antibody [SP189] - C-terminal

  • Carrier free

    Anti-CD16a antibody [SP189] - BSA and Azide free

  • 578 PE

    PE Anti-CD16 antibody [SP189] (C-terminal)

  • HRP

    HRP Anti-CD16 antibody [SP189] (C-terminal)

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

SP189

Isotype

IgG

Conjugation

APC

Excitation/Emission

Ex: 650nm, Em: 660nm

Carrier free

No

Applications

Target Binding Affinity, Antibody Labelling

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

You may be interested in:

AB277469

Human CD16 ELISA Kit

0

0 Reviews

View product

We recommend this product because it’s often used in the same experiment or related research.

We advise that you always check the datasheet to ensure it fits your experiments, or contact ourtechnical teamfor help.

Product details

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link® conjugation technology, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations.

For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A/G
Purification notes
Purified from TCS by protein A/G.
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: 98% PBS, 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The CD16a protein also known as Fc gamma receptor IIIa (FcγRIIIa) plays an important role in the immune system. This receptor is about 50-70 kDa in mass and is expressed on the surface of natural killer (NK) cells macrophages and some T cells. CD16a facilitates antibody-dependent cellular cytotoxicity (ADCC) by binding to the Fc region of immunoglobulin G (IgG). This interaction allows effector immune cells to recognize and destroy antibody-coated target cells.
Biological function summary

CD16a is important for immune responses and occurs as part of a receptor complex. It signals downstream effects through its association with the CD3 zeta chain and the Fc epsilon receptor gamma chain which possess immunoreceptor tyrosine-based activation motifs (ITAMs). Upon binding to IgG CD16a triggers a cascade of events leading to the release of cytokines and cytotoxic granules. This action helps in eliminating infected or cancerous cells demonstrating its role in both innate and adaptive immunity.

Pathways

CD16a contributes significantly to the immunological synapse formation and NK cell activation pathway. This receptor cooperates with other proteins such as CD3 and CD19 to modulate the immune response. It also participates in signaling pathways like the PI3K-Akt pathway which regulates cell survival and proliferation. CD16a's interaction with these pathways highlights its importance in immune cell communication and function.

CD16a is linked to autoimmune diseases and certain cancers. In autoimmune disorders like systemic lupus erythematosus (SLE) abnormal CD16a function can contribute to the pathogenesis by altering immune cell targeting. Additionally in cancers such as lymphoma CD16a's interaction with IgG-coated cancer cells can influence the efficacy of monoclonal antibody therapies. The receptor's association with proteins like CD3 and CD19 in these disease contexts highlights its potential as a therapeutic target.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). Does not bind free monomeric IgG, thus avoiding inappropriate effector cell activation in the absence of antigenic trigger (PubMed : 11711607, PubMed : 21768335, PubMed : 22023369, PubMed : 24412922, PubMed : 25786175, PubMed : 25816339, PubMed : 28652325, PubMed : 8609432, PubMed : 9242542). Mediates IgG effector functions on natural killer (NK) cells. Binds antigen-IgG complexes generated upon infection and triggers NK cell-dependent cytokine production and degranulation to limit viral load and propagation. Involved in the generation of memory-like adaptive NK cells capable to produce high amounts of IFNG and to efficiently eliminate virus-infected cells via ADCC (PubMed : 24412922, PubMed : 25786175). Regulates NK cell survival and proliferation, in particular by preventing NK cell progenitor apoptosis (PubMed : 29967280, PubMed : 9916693). Fc-binding subunit that associates with CD247 and/or FCER1G adapters to form functional signaling complexes. Following the engagement of antigen-IgG complexes, triggers phosphorylation of immunoreceptor tyrosine-based activation motif (ITAM)-containing adapters with subsequent activation of phosphatidylinositol 3-kinase signaling and sustained elevation of intracellular calcium that ultimately drive NK cell activation. The ITAM-dependent signaling coupled to receptor phosphorylation by PKC mediates robust intracellular calcium flux that leads to production of pro-inflammatory cytokines, whereas in the absence of receptor phosphorylation it mainly activates phosphatidylinositol 3-kinase signaling leading to cell degranulation (PubMed : 1825220, PubMed : 23024279, PubMed : 2532305). Costimulates NK cells and trigger lysis of target cells independently of IgG binding (PubMed : 10318937, PubMed : 23006327). Mediates the antitumor activities of therapeutic antibodies. Upon ligation on monocytes triggers TNFA-dependent ADCC of IgG-coated tumor cells (PubMed : 27670158). Mediates enhanced ADCC in response to afucosylated IgGs (PubMed : 34485821).. (Microbial infection) Involved in Dengue virus pathogenesis via antibody-dependent enhancement (ADE) mechanism. Secondary infection with Dengue virus triggers elevated levels of afucosylated non-neutralizing IgG1s with reactivity to viral envelope/E protein. Viral antigen-IgG1 complexes bind with high affinity to FCGR3A, facilitating virus entry in myeloid cells and subsequent viral replication.
See full target information FCGR3A

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Associated Products

Select an associated product type
Alternative Version
Primary Antibodies

AB243936

Anti-CD16a antibody [SP189] - BSA and Azide free

primary-antibodies

cd16a-antibody-sp189-bsa-and-azide-free-ab243936

0

(0 reviews)

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com